Dacomitinib increases Survival Rates in Lung Cancer Patients

Editor's Note: This article originally appeared on ASCO News

Phase III clinical trials show promise in delaying the growth of cancer in patients with EFGR-positive non-small cell lung cancer with a new second generation targeted inhibitor, dacomitinib.

Patients who received this new inhibitor over another inhibitor, gefitinib, had a 41% lower chance of cancer progression.

Read more from the original article on ASCO

PrecisionPlan for Oncology Professionals

Build Actionable, Patient-Specific Cancer Treatment Plans

Integrate or embed our cognitive computing platform into your health system or cancer center EMR to make optimal, personalized, and patient-centered decisions.

Our codified clinical knowledge allows for expert-to-expert consultations and actionable patient-specific pathways built in seconds. 

PrecisionPlan™ is a comprehensive and continuum-based platform that outlines in detail the most appropriate clinical guidance in chemotherapy, immunotherapy, genomic-guided targeted therapy, anti-hormonal therapy, radiation therapy, surgery, supportive care, palliative care and follow up/survivorship that is unique to each patient.

Topics: